IP Library Granted Patent US 10,124,035
Granted Patent B2
US 10,124,035 · App. 13/608,166 · Granted Nov 13, 2018

DISC-1 pathway activators in the control of neurogenesis

Inventors: Li-Huei Tsai (Cambridge, MA); Yingwei Mao (Arlington, MA); Jon Madison (Newton, MA); Stephen J. Haggarty (Gloucester, MA)
Assignees: Massachusetts Institute of Technology; The General Hospital Corporation
A61K38/1709A61K31/00A61K31/351A61K31/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,124,035
App. No.
13/608,166
Granted
Nov 13, 2018
Kind
B2
Abstract

The invention relates to methods of treating neurological disorders in a subject, by activating a DISC1 pathway. Methods of promoting neurogenesis in adult neural progenitor cells, enhancing nerve generation and treating GSK3 disorders as well as related compositions are also provided.

Claims (3)

1. A method of treating a neurological disorder in a subject, comprising administering to a subject a DISC1 activator in an effective amount to treat the neurological disorder, wherein when the DISC1 activator is a DISC1 agonist, the DISC1 agonist is not an exogenous full length DISC1 nucleic acid or polypeptide, wherein the DISC1 agonist is a DISC1 fragment, wherein the neurological disorder is a neurodegenerative disease and wherein the neurodegenerative disease is dementia.

2. A method of enhancing neural progenitor proliferation and differentiation, comprising contacting a neural progenitor cell with a DISC1 activator in an effective amount to enhance neural progenitor proliferation and differentiation, wherein when the DISC1 activator is a DISC1 agonist, the DISC1 agonist is not an exogenous full length DISC1 nucleic acid or polypeptide, wherein the DISC1 agonist is a DISC1 fragment consisting of the amino acid sequence of SEQ ID No. 8.

3. A method of enhancing nerve generation, comprising contacting a nerve with a DISC1 activator in an effective amount to enhance nerve generation, wherein when the DISC1 activator is a DISC1 agonist, the DISC1 agonist is not a full length DISC1 exogenous nucleic acid or polypeptide, wherein the DISC1 agonist is a DISC1 fragment consisting of the amino acid sequence of SEQ ID No. 8.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 029102 FRAME 0386. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 22, 2018
From: HAGGARTY, STEPHEN
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 045102/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2012
From: HAGGARTY, STEPHEN
To: THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL
Reel/Frame 029102/0386 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2012
From: TSAI, LI-HUEI; MAO, YINGWEI; MADISON, JON
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 029102/0433 →
Continuity (4)
Continuation 12474229 · May 28, 2009
Provisional Application 61155973 · Feb 27, 2009
Provisional Application 61130071 · May 28, 2008
Related Publication 20130004517A1 · Jan 3, 2013